Anti-FGF23 Dosing Regimens for Stable Serum Phosphate Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more effective methods to treat disorders related to abnormal phosphate metabolism, such as those associated with fibroblast growth factor-23 (FGF23) signaling, and to evaluate the efficacy of such treatments.
Innovation Solution
Determine a dosing regimen for anti-FGF23 ligands based on PD parameters like serum phosphorus levels, Tmp/GFR, and vitamin D levels to effectively treat conditions like autosomal dominant hypophosphatemic rickets, X-linked hypophosphatemia, and other disorders by administering anti-FGF23 ligands such as antibodies or oligonucleotides, which can include specific CDR sequences, to achieve a stable increase in phosphate levels and sustain NaPi transporter activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-FGF23 ligands are administered to treat disorders related to abnormal phosphate metabolism, then phosphate levels increase and therapeutic effect is achieved, but dosing regimen complexity increases and treatment efficacy evaluation becomes more difficult
Solution Approach 1:
The patent employs feedback mechanisms by monitoring serum phosphate levels and FGF23 levels to adjust dosing regimens. The method determines dosing intervals based on the relationship between phosphate levels and regulated levels of FGF23 within a dosing cycle, allowing dynamic adjustment of treatment parameters to maintain therapeutic efficacy while simplifying the overall dosing strategy through data-driven decision making.
Solution Approach 2:
The patent utilizes parameter changes by establishing specific thresholds and ranges for phosphate levels and FGF23 levels to guide dosing decisions. By defining predetermined ranges for these parameters and adjusting dosing regimens based on measured values within these ranges, the method transforms complex treatment optimization into a systematic parameter-based approach that improves reliability while managing complexity.
2Reliability
If dosing regimen is optimized based on phosphate levels and FGF23 levels, then treatment efficacy is improved, but measurement and monitoring requirements increase
Solution Approach 1:
The patent applies preliminary action by establishing baseline measurements of phosphate levels and FGF23 levels before initiating treatment. By determining the relationship between these parameters in advance and creating a dosing regimen based on baseline data, the method reduces the need for frequent intensive monitoring during treatment, as the dosing schedule is pre-optimized based on initial measurements.
Solution Approach 2:
The method enables self-service by using the patient's own measured phosphate and FGF23 levels to determine their dosing regimen. The relationship between these parameters serves as an intrinsic guide for treatment optimization, eliminating the need for external complex assessment systems and allowing the treatment protocol to be tailored automatically based on individual patient data.
Data Source
AI summary
The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.